Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
G Folprecht, C Pericay, MP Saunders, A Thomas, R Lopez Lopez, JK Roh, V Chistyakov, T Hoehler, J-S Kim, R-D Hofheinz, SP Ackland, D Swinson, M Kopp, D Udovitsa, M Hall, T Iveson, A Vogel, JR Zalcberg
Annals of Oncology | OXFORD UNIV PRESS | Published : 2016
This study was funded by Sanofi, in collaboration with Regeneron Pharmaceuticals, Inc. (no grant number). Employees of Sanofi were involved in the study design, the collection, analysis and interpretation of data. The Medical Affairs Departments at Sanofi and Regeneron were allowed several reviews by the authors for scientific accuracy, and provided feedback to the authors for their consideration. Editorial assistance in the preparation of this manuscript was provided by Dr George Xinarianos (Cancer Communications Ltd, Knutsford, UK), and funded by Sanofi (Cambridge, MA), in collaboration with Regeneron Pharmaceuticals, Inc. (Tarrytown, NY). Sanofi and Regeneron were not involved in the writing or editing of this manuscript, and were not permitted to censor any content from the authors.